Skip to main content
NoticePayment processing is currently down, so we are not taking new orders right now. Thank you for your patience.
For laboratory research use only. Not for human or veterinary use.
Free UPS Ground on 3+ vials · same business day by 2 PM ET
GLP-1 family

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer X, Astrup A, Fujioka K, et al. · N Engl J Med · 2015
PMID: 26132939 · DOI: 10.1056/NEJMoa1411892
Summary

56-week double-blind randomized trial (SCALE) in 3731 adults without type 2 diabetes; once-daily subcutaneous liraglutide 3.0 mg vs placebo, both with lifestyle counseling. Primary endpoint: change in body weight.

Read the full citation on PubMed

Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.

Compounds referenced in this study
  • GLP-1 S
    Single-receptor incretin class agonist studied in incretin-pathway metabolic research.
    View product →
Guides covering this compound
More GLP-1 family citations
Browse the catalog